Alisertib (MLN8237)

製品コードS1133

Alisertib (MLN8237)化学構造

分子量(MW):518.92

Alisertib (MLN8237)は一種の選択性オーロラ(Aurora )A阻害剤で、無細胞試験でIC50値が1.2 nMです。Alisertib (MLN8237)はオーロラAに作用する選択性はオーロラ Bに作用する選択性より200倍以上が高くなります。臨床3期。

サイズ 価格(税別) 在庫  
JPY 27888.00 あり
JPY 19920.00 あり
JPY 34860.00 あり
JPY 111220.00 あり

文献中の使用例(48)

カスタマーフィードバック(12)

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

製品安全説明書

Aurora Kinase阻害剤の選択性比較

生物活性

製品説明 Alisertib (MLN8237)は一種の選択性オーロラ(Aurora )A阻害剤で、無細胞試験でIC50値が1.2 nMです。Alisertib (MLN8237)はオーロラAに作用する選択性はオーロラ Bに作用する選択性より200倍以上が高くなります。臨床3期。
特性 First orally available inhibitor of Aurora A.
ターゲット
Aurora A [1]
(Cell-free assay)
1.2 nM
体外試験

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 M{Xqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rMSlAvPSEQvF2= NFfrTXc4OiCq MkXiSG1UVw>? NWmxc|NPUUN3ME2wMlA1KM7:TR?= M4nJOVI3OTN4Nki0
LS174T MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PodFAvPSEQvF2= NYTmWml[PzJiaB?= NF\O[3FFVVOR NHXTSmxKSzVyPUCuNFUh|ryP MYCyOlE{PjZ6NB?=
T84 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfy[4UxNjVizszN NH3SNXE4OiCq M3fjVmROW09? NX3vfGJTUUN3ME2wMlA6KM7:TR?= MnPmNlYyOzZ4OES=
LS180 NHjKTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r5b|AvPSEQvF2= NG\UR|I4OiCq MWDEUXNQ MX;JR|UxRTFizszN M2XFWFI3OTN4Nki0
SW948 M4DvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojGNE42KM7:TR?= MojpO|IhcA>? MXfEUXNQ NHTXe3JKSzVyPUGg{txO NWK5NXBrOjZzM{[2PFQ>
HCT15 NYf6c25rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HYVVAvPSEQvF2= MWm3NkBp NXL3NmF2TE2VTx?= MnrxTWM2ODxyLkSg{txO M4X5NVI3OTN4Nki0
DLD-1 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUewMlUh|ryP MXG3NkBp Ml7SSG1UVw>? NVHWS4FMUUN3MEywMlgh|ryP NIjGToozPjF|Nk[4OC=>
MIP-101 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPzNE42KM7:TR?= M3j2cFczKGh? MXPEUXNQ MkiwTWM2OD1zIN88US=> NHrBUGIzPjF|Nk[4OC=>
SNU1544 M2rkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnpcZYxNjVizszN NXqz[I1QPzJiaB?= M4jWcmROW09? MV3JR|UxRTFizszN MW[yOlE{PjZ6NB?=
OCI-Ly10 MnvqR5l1d3SxeHnjJGF{e2G7 NF23dIw4OiCq NHPKVplFVVOR M2ruWmlEPTB;MD6wOVgh|ryP NHPCZ4szPTh5OEOzNS=>
SU-DHL2 NXvRTHB{S3m2b4TvfIlkKEG|c3H5 NYTzcWZCPzJiaB?= Mm\0SG1UVw>? M1PzeWlEPTB;MD6wNUDPxE1? NFfZSXozPTh5OEOzNS=>
OCI-LY7 MWjDfZRwfG:6aXOgRZN{[Xl? MmDUO|IhcA>? NH:zUZhFVVOR MXzJR|UxRTBwMEixJO69VQ>? NV;MbW5JOjV6N{izN|E>
SU-DHL6 MVLDfZRwfG:6aXOgRZN{[Xl? NYDI[YdVPzJiaB?= M3f5U2ROW09? NEPkTVlKSzVyPUCuOFgzKM7:TR?= MWKyOVg4QDN|MR?=
Jeko-1 MV7DfZRwfG:6aXOgRZN{[Xl? M1rqeVczKGh? MXXEUXNQ M4nKdGlEPTB;MD6wNlkh|ryP MoDCNlU5Pzh|M{G=
JVM-2 MUnDfZRwfG:6aXOgRZN{[Xl? MYW3NkBp MnjrSG1UVw>? M{\4R2lEPTB;MD6wNUDPxE1? M1;1RlI2QDd6M{Ox
Rec-1 MlTDR5l1d3SxeHnjJGF{e2G7 MmDzO|IhcA>? MoDsSG1UVw>? MnrITWM2OD1yLkC4O{DPxE1? MWiyOVg4QDN|MR?=
Z-138 MWHDfZRwfG:6aXOgRZN{[Xl? MlK3O|IhcA>? MlLTSG1UVw>? M3rWNWlEPTB;MD6wNVMh|ryP NWH2XGlwOjV6N{izN|E>
H9 M2\qVmN6fG:2b4jpZ{BCe3OjeR?= NYHFd45FPzJiaB?= NEKyTmZFVVOR M1XO[WlEPTB;MD62JO69VQ>? NH3xPVUzPTh5OEOzNS=>
HH NH7rN5VEgXSxdH;4bYMhSXO|YYm= MkfBO|IhcA>? M4XxbGROW09? NGrCUHhKSzVyPUCuO{DPxE1? MV[yOVg4QDN|MR?=
DND41 MV\DfZRwfG:6aXOgRZN{[Xl? M1ziXFczKGh? MXrEUXNQ NVPGZpVwUUN3ME2wMlEh|ryP NULOOINZOjV6N{izN|E>
CCL119 MX3DfZRwfG:6aXOgRZN{[Xl? MV[3NkBp MoH2SG1UVw>? NXfCXIpLUUN3ME2wMlA3OiEQvF2= Ml3rNlU5Pzh|M{G=
J.Cam 1.6 NHS1XpNEgXSxdH;4bYMhSXO|YYm= M1fXO|czKGh? MUDEUXNQ Mn;aTWM2OD1yLkGwOUDPxE1? M1fxcVI2QDd6M{Ox
Sup-T1 MUnDfZRwfG:6aXOgRZN{[Xl? NGew[og4OiCq NGjCcotFVVOR NFTr[pFKSzVyPUKuNVQzKM7:TR?= MXWyOVg4QDN|MR?=
Tib 152 Mn24R5l1d3SxeHnjJGF{e2G7 MUC3NkBp MX3EUXNQ NF\McVdKSzVyPUCuPEDPxE1? Mlj2NlU5Pzh|M{G=
MCF7 NGTtVJFHfW6ldHnvckBCe3OjeR?= MoPIOUDPxE1? NHm0d|MzPCCq NGTWTXlFVVOR NWfMU2xGUW6mdXPld{BIOi:PIHHydoV{fA>? NIH0XHQzPTh|NESwNS=>
MDA-MB-231 NGKxXoNHfW6ldHnvckBCe3OjeR?= M3S3cVUh|ryP NYnHZpJnOjRiaB?= NXrZU|VWTE2VTx?= MnfxTY5lfWOnczDHN{9OKGG{cnXzeC=> MYGyOVg{PDRyMR?=
MCF7 NGjRT2tHfW6ldHnvckBCe3OjeR?= NGnZW4g2KM7:TR?= M{jWW|I1KGh? NVS0bGcxTE2VTx?= NIP2N2ZF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy NWjSTHV{OjV6M{S0NFE>
MCF7 MXHGeY5kfGmxbjDBd5NigQ>? M4\2fFUh|ryP MVKyOEBp MWnEUXNQ MnS5SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> NYXGN4VjOjV6M{S0NFE>
MCF7 MWDGeY5kfGmxbjDBd5NigQ>? NHXsXZY2KM7:TR?= NHTRSoYzPCCq NETEemlFVVOR NHy0R3VF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx NHPkOnIzPTh|NESwNS=>
MCF7 MVjGeY5kfGmxbjDBd5NigQ>? MWi1JO69VQ>? NX7HbWlnOjRiaB?= M1KxR2ROW09? Mn76TY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> MkK1NlU5OzR2MEG=
MCF7 NYXkdWwxTnWwY4Tpc44hSXO|YYm= NGD6S4k2KM7:TR?= MljvNlQhcA>? M{G3bWROW09? NH3W[VlKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= NFrWRZkzPTh|NESwNS=>
MDA-MB-231 M4Sz[2Z2dmO2aX;uJGF{e2G7 NIS0NXM2KM7:TR?= NYHvcXh7OjRiaB?= MXLEUXNQ MXXE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ M1;5WFI2QDN2NECx
MDA-MB-231 NFzGbYFHfW6ldHnvckBCe3OjeR?= MWOxJO69VQ>? NXrUWlNROjRiaB?= MWXEUXNQ NVnZSWI{UW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzJ? MoL4NlU5OzR2MEG=
MDA-MB-231 NHvPeINHfW6ldHnvckBCe3OjeR?= NFvwZZM2KM7:TR?= NHvLO|QzPCCq MlHiSG1UVw>? MoK4SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?= MoHLNlU5OzR2MEG=
MDA-MB-231 MXTGeY5kfGmxbjDBd5NigQ>? MlnKOUDPxE1? MmjONlQhcA>? MkLySG1UVw>? MljvTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> M2LRblI2QDN2NECx
MDA-MB-231 NHezW4RHfW6ldHnvckBCe3OjeR?= MUG1JO69VQ>? M2HodlI1KGh? MV7EUXNQ NILoOHVKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= Ml\sNlU5OzR2MEG=
MDA-MB-231 M1rlNmZ2dmO2aX;uJGF{e2G7 NFPjboo2KM7:TR?= MX6yOEBp NYi0fIVtTE2VTx?= NVLjWZF3UW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJA2Ow>? NVS1OZVLOjV6M{S0NFE>
MCF7 MVfBdI9xfG:|aYOgRZN{[Xl? MY[1JO69VQ>? NGPpXGszPCCq M37PW2ROW09? MUPJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? M3TsTlI2QDN2NECx
MDA-MB-231 MkLCRZBweHSxc3nzJGF{e2G7 M3jheVUh|ryP MWqyOEBp NF35UJZFVVOR NFjtTG5KdmS3Y3XzJIFxd3C2b4TpZ{Bl\WG2aB?= M1e4dlI2QDN2NECx
MCF7 NUToRmtQTnWwY4Tpc44hSXO|YYm= NHO4cmkyKM7:TR?= MnjuO|IhcA>? NUDDZYZuTE2VTx?= NYL5U4I1UW6mdXPld{BifXSxcHjh[4lkKGSnYYTo NHnOUmIzPTh|NESwNS=>
MDA-MB-231 MVnGeY5kfGmxbjDBd5NigQ>? M2PqelEh|ryP NV3NTnk3PzJiaB?= MUXEUXNQ NFfQ[oFKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= NF35WIIzPTh|NESwNS=>
U-2 OS NUX6eIFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK1NEDPxE1? NF;rbW0zPCCq MWTEUXNQ M1XPT2lEPTB;MU[uOkDPxE1? NWPQTI5rOjV5OUK4NVE>
MG-63 NGDEZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\hOVAh|ryP MWKyOEBp MXPEUXNQ M{TTWmlEPTB;OT61JO69VQ>? MUSyOVc6OjhzMR?=
U-2 OS MYPBdI9xfG:|aYOgRZN{[Xl? NVPwXYM4PSEQvF2= MlzKNlQhcA>? MXHEUXNQ NHnQbXJKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp NIm0em4zPTd7MkixNS=>
MG-63 NYHEclZ7SXCxcITvd4l{KEG|c3H5 MkfWOUDPxE1? MmDCNlQhcA>? M3TjfmROW09? M17XTGlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> M1i5NFI2Pzl{OEGx
U-2 OS M{ftcWZ2dmO2aX;uJGF{e2G7 MX21JO69VQ>? Mn3MNlQhcA>? NUHBfXZCTE2VTx?= NVPKeYtOWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq MUWyOVc6OjhzMR?=
MG-63 NELEZpBHfW6ldHnvckBCe3OjeR?= NYrqTIJ{PSEQvF2= MYWyOEBp NF;4XpJFVVOR NX7SSY0zWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq M1nCS|I2Pzl{OEGx
PANC-1 NInxeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmToOVAh|ryP NHfDTmwzPCCq NGHJdIhFVVOR M1zjPGlEPTB;Nz6xJO69VQ>? M{fBclI2PjN{MkK1
BxPC-3 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TBZ|UxKM7:TR?= MYSyOEBp MWjEUXNQ MWXJR|UxRTZwODFOwG0> MUCyOVY{OjJ{NR?=
PANC-1 M1jVdmZ2dmO2aX;uJGF{e2G7 NYLTZ4lxPSEQvF2= NFLU[JYzPCCq MoDYSG1UVw>? NEXKeVhKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V? M4K5PFI2PjN{MkK1
BxPC-3 Ml7PSpVv[3Srb36gRZN{[Xl? MX:1JO69VQ>? MVuyOEBp MlnDSG1UVw>? NWft[3V7UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn MmW4NlU3OzJ{MkW=
PANC-1 M4K2WmZ2dmO2aX;uJGF{e2G7 M3PzT|Uh|ryP M3\SRlI1KGh? MYHEUXNQ NEfnelVKdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? NYi0XZZYOjV4M{KyNlU>
BxPC-3 NGC3dnBHfW6ldHnvckBCe3OjeR?= NH:3O|U2KM7:TR?= NX7IUZh5OjRiaB?= NIniTmdFVVOR MkLlTY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> MX2yOVY{OjJ{NR?=
SKOV3 MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;pTlFzOTByIN88US=> NETaS|UzPCCq MlzRSG1UVw>? MXXJR|UxRTJyLkS4JO69VQ>? NXnoUnZEOjV4MkS3OVA>
OVCAR4 MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\TTnEyODBizszN NXLiW5htOjRiaB?= MkDwSG1UVw>? NIf2R5ZKSzVyPUKyMlE{KM7:TR?= NFTSNVkzPTZ{NEe1NC=>
SKOV3 M13IU2Z2dmO2aX;uJGF{e2G7 NVrrO|N4PSEQvF2= MlX3O|IhcA>? MlrHSG1UVw>? MlPSTY5lfWOnczDHNk9OKGG{cnXzeC=> M4DrdFI2PjJ2N{Ww
OVCAR4 MYLGeY5kfGmxbjDBd5NigQ>? NVftUIFiPSEQvF2= MoD6O|IhcA>? NFTqcZVFVVOR NVizU49pUW6mdXPld{BIOi:PIHHydoV{fA>? NFuyOHUzPTZ{NEe1NC=>
SKOV3 NGTafVhCeG:ydH;zbZMhSXO|YYm= NVvz[pJPPSEQvF2= Mo\pNlQhcA>? MmrhSG1UVw>? MVLJcoR2[2W|IHHwc5B1d3Orcx?= M2XsPVI2PjJ2N{Ww
OVCAR4 MlTTRZBweHSxc3nzJGF{e2G7 NWrtcZlRPSEQvF2= NWDFWJJMOjRiaB?= MUfEUXNQ NGDaeZJKdmS3Y3XzJIFxd3C2b4Ppdy=> M1LFe|I2PjJ2N{Ww
AGS NVTJRXVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme4NlUh|ryP MoTkNlQhcA>? NGfrN3BFVVOR NUPX[VNLUUN3ME2xPU4xQSEQvF2= MX6yOVYxQTl{Mx?=
NCI-N78 M3TCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M131TlI2KM7:TR?= M3jEeVI1KGh? MWLEUXNQ MoWwTWM2OD1{Nj6zN{DPxE1? NVfJWIMyOjV4MEm5NlM>
AGS NELheXFCeG:ydH;zbZMhSXO|YYm= MoPrOUDPxE1? NYjkNnM3OjRiaB?= MUHEUXNQ NFfaTnZKdmS3Y3XzJIFxd3C2b4Ppdy=> M4DnS|I2PjB7OUKz
NCI-N78 MoToRZBweHSxc3nzJGF{e2G7 M33icFUh|ryP MlXkNlQhcA>? MYTEUXNQ M3y0NGlv\HWlZYOgZZBweHSxc3nz M4TIOVI2PjB7OUKz
AGS NIDQdXhHfW6ldHnvckBCe3OjeR?= NGnDTG02KM7:TR?= M4PpWlI1KGh? NH\QbW1FVVOR NWX0ZmdWUW6mdXPld{B1cGViYYX0c5Bp[We7 MX:yOVYxQTl{Mx?=
NCI-N78 M1L5c2Z2dmO2aX;uJGF{e2G7 NIX3TVg2KM7:TR?= MkPRNlQhcA>? M3TxOWROW09? MX7JcoR2[2W|IITo[UBifXSxcHjh[5k> NXe5PYpDOjV4MEm5NlM>
HSC-3 NF3hdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:2fXoyKM7:TR?= MojUOFghcA>? MVHJR|UxRTBwNUSg{txO M1jkV|I2OzZ4MUSz
GB30 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxJO69VQ>? NV7RTGZQPyCm NH3xXGNFVVOR NV\CT|VjUUN3ME2wMlAyOSEQvF2= MknrNlUyODZ2Mki=
GB9 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnrNUDPxE1? M{H5Rlch\A>? MXXEUXNQ MYrJR|UxRTBwMEK0JO69VQ>? NWGxT29YOjVzME[0Nlg>
GB169 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPvb2oyKM7:TR?= M4rTUVch\A>? NI\peFhFVVOR MVXJR|UxRTBwMEOyJO69VQ>? MXWyOVExPjR{OB?=
T24 Mny0SpVv[3Srb36gRZN{[Xl? MlSzNUDPxE1? M4jCd|Q5KGh? MVzEUXNQ MUfJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MlTTNlM1ODN4M{O=
RT4 NIDnU4VHfW6ldHnvckBCe3OjeR?= MlTGNUDPxE1? M4nMZVQ5KGh? NXjCSVJJTE2VTx?= NHHCWHpKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NVftUXVuOjN2MEO2N|M>
UM-UC-3 Mm\3SpVv[3Srb36gRZN{[Xl? NXvXbYNROSEQvF2= MVi0PEBp MXfEUXNQ NGfmN3VKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NVTpVJBUOjN2MEO2N|M>
T24 MkT2RZBweHSxc3nzJGF{e2G7 NUjkeGxROy5zNjFOwG0> M1HLSlk3KGh? NGPx[YRFVVOR NWntWWdtUUN3ME2wMlA{ODZizszN MV[yN|QxOzZ|Mx?=
RT4 NHPhemNCeG:ydH;zbZMhSXO|YYm= NV\vOmZ4Oy5zNjFOwG0> M2LobVk3KGh? NIn2S3RFVVOR NHiySHBKSzVyPUCuNVE6QCEQvF2= M2XINlI{PDB|NkOz
UM-UC-3 MWHBdI9xfG:|aYOgRZN{[Xl? M2TkWFMvOTZizszN NWDxS5NMQTZiaB?= M2G2e2ROW09? MVvJR|UxRTBwMES0PUDPxE1? NHvCOlQzOzRyM{[zNy=>
OVCAR-5 NVrhd|RsTnWwY4Tpc44hSXO|YYm= MXW1NEBvVQ>? NXm2S|MxUW6qaXLpeJMh[2WubDDtbYdz[XSrb36= MV6yN|M{PDN{Nx?=
SKOV3ip2 MkXkSpVv[3Srb36gRZN{[Xl? MU[1NEBvVQ>? NVXPNHZbUW6qaXLpeJMh[2WubDDtbYdz[XSrb36= MWGyN|M{PDN{Nx?=
S462 NIPCS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSxNFAh|ryP NV\sUnZ5PzJiaB?= NYrUVpcyTE2VTx?= NGq1SmRCfHSnboXheIV{KGOnbHyg[5Jwf3Sq MXqyN|MzQDFzNB?=
2884 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHsN5dFOTByIN88US=> M{HUb|czKGh? NULFXmNoTE2VTx?= NGXETWFCfHSnboXheIV{KGOnbHyg[5Jwf3Sq NU[2T4NnOjN|MkixNVQ>
2885 NFXTeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj0NVAxKM7:TR?= MmjhO|IhcA>? MmPqSG1UVw>? M1LVb2F1fGWwdXH0[ZMh[2WubDDndo94fGh? M3;sclI{OzJ6MUG0
CRL-2396 NIHvV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16wWlExOCEQvF2= NG\1dI14[XSnch?= MkfOTWM2OD1yLkC5NkDPxE1? MoLoNlMyPTN3MkS=
TIB-48 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Ww[FExOCEQvF2= MWn3ZZRmeg>? NUjid3EyUUN3ME2wMlA5QCEQvF2= M4HYVVI{OTV|NUK0
CRL-2396 M{O0fmN6fG:2b4jpZ{BCe3OjeR?= MoLVNUDPxE1? NF65U|g1QCCq MoTBe4F1\XJ? MnLFTY5lfWOnczDhdI9xfG:|aYO= M1;1OFI{OTV|NUK0
TIB-48 M2Lrb2N6fG:2b4jpZ{BCe3OjeR?= NWXNNGJqOSEQvF2= MlK0OFghcA>? NH76WZB4[XSnch?= MoraTY5lfWOnczDhdI9xfG:|aYO= NHvRRnIzOzF3M{WyOC=>
AGS Ml3yR5l1d3SxeHnjJGF{e2G7 MUmwMlUh|ryP MlvzNlQhcA>? NID1NpNFVVOR NYLhUoNFTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= NGrDO5MzOjl5Mk[xNS=>
FLO-1 NX25TIE1S3m2b4TvfIlkKEG|c3H5 NGLSXooxNjVizszN M1GxTVI1KGh? MX\EUXNQ MUXE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? MofpNlI6PzJ4MUG=
OE33 NFPifoxEgXSxdH;4bYMhSXO|YYm= MWKwMlUh|ryP MYKyOEBp M1HyXWROW09? M4DjW2Rm[3KnYYPld{Bk\WyuIIP1dpZqfmGu M3\TblIzQTd{NkGx
SKLMS MnW3R5l1d3SxeHnjJGF{e2G7 NHe1OmU4PSCwTR?= NXT2WlRNQTZiaB?= M4L1eGlv\HWlZYOgZZBweHSxc3nz NIfxUlkzOjh{MUm5Oy=>
Leio285 M2W5WmN6fG:2b4jpZ{BCe3OjeR?= M4nUfFc2KG6P MWK5OkBp NH\hW2tKdmS3Y3XzJIFxd3C2b4Ppdy=> NGq1XnczOjh{MUm5Oy=>
Mes-Sa NVfGT2VQS3m2b4TvfIlkKEG|c3H5 MkfGO|Uhdk1? MknKPVYhcA>? M1\5SGlv\HWlZYOgZZBweHSxc3nz M3n4PFIzQDJzOUm3
DAOY MnjRR5l1d3SxeHnjJGF{e2G7 NFrEUXcyOCEQvF2= MXK3NkBp MVHEUXNQ M{W4cWlEPTB;MD6wOEDPxE1? MnHUNlI3Pjl|M{W=
IMR32 M3HHOWN6fG:2b4jpZ{BCe3OjeR?= MmTRNVAh|ryP MYC3NkBp NWiy[3J2TE2VTx?= M2Ds[GlEPTB;MD6wN{DPxE1? MYmyNlY3QTN|NR?=
Molt-4 NV7WcJh1S3m2b4TvfIlkKEG|c3H5 MlHTNVAh|ryP M4XZTVczKGh? M1L3UmROW09? MXnJR|UxRTBwMEKg{txO Mo\JNlI3Pjl|M{W=
MOLM-13 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zrb|Mh|ryP NFXkTlk4OiCq MUTEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MVKyNlQ5QDJ2OR?=
HL-60 NYT2fGNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqzJO69VQ>? NGW1dHg4OiCq NYfxfm1QTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NUPN[YtUOjJ2OEiyOFk>
MV4-11 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr1XWU{KM7:TR?= M4LEUlczKGh? M1G5NGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NXvacoF5OjJ2OEiyOFk>
SKM-1 NXPDb2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUezJO69VQ>? NUfXd4hSPzJiaB?= M1vnb2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NF7VfmUzOjR6OEK0PS=>
SH2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK3flI{KM7:TR?= MV[3NkBp MWTEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NV61S4ttOjJ2OEiyOFk>
NOMO-1 NUP4UYJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfZZVY{KM7:TR?= NUCyV4o3PzJiaB?= M1fkOGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MlnzNlI1QDh{NEm=
OCL-AML2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M36zdFMh|ryP MYe3NkBp MnfaSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MYKyNlQ5QDJ2OR?=
PL-21 MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW2R|NiOyEQvF2= M2foXVczKGh? MkjQSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NIrFVlIzOjR6OEK0PS=>
KG-1 NX3qPINXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:0SZU{KM7:TR?= MUG3NkBp M1vCV2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MnTTNlI1QDh{NEm=
A172 M{D6VmN6fG:2b4jpZ{BCe3OjeR?= MmPrNVAxKM7:TR?= MUmyOEBp M{C0SGROW09? MXLJR|UxRTBwMUKwJO69VQ>? NV\BdI5SOjJ{N{SzPVk>
U87 MWHDfZRwfG:6aXOgRZN{[Xl? MnX2NVAxKM7:TR?= NUDiS2lUOjRiaB?= MnvRSG1UVw>? NHLkRYNKSzVyPUCuNVA2KM7:TR?= MlTiNlIzPzR|OUm=
U251 MVHDfZRwfG:6aXOgRZN{[Xl? M3vmWVExOCEQvF2= MWWyOEBp M3Swe2ROW09? MlK1TWM2OD1yLkGwNEDPxE1? MkTENlIzPzR|OUm=
T98 NED3NJVEgXSxdH;4bYMhSXO|YYm= NFyy[GIyODBizszN MkX5NlQhcA>? MYPEUXNQ MUPJR|UxRTBwMUK1JO69VQ>? M2PS[FIzOjd2M{m5
LN18 Mnv3R5l1d3SxeHnjJGF{e2G7 NYnDb4w3OTByIN88US=> NHXIR3gzPCCq M3G2[mROW09? MUTJR|UxRTBwMkGwJO69VQ>? MYmyNlI4PDN7OR?=
LN443 MYfDfZRwfG:6aXOgRZN{[Xl? NWCxUY1uOTByIN88US=> M4jkOlI1KGh? M{TPWmROW09? MmPlTWM2OD1yLkKyNEDPxE1? NXzOPHA1OjJ{N{SzPVk>
HF66 MnizR5l1d3SxeHnjJGF{e2G7 Mn7kNVAxKM7:TR?= NVHOT3hKOjRiaB?= M3LFO2ROW09? M1TMV2lEPTB;MD6yNlUh|ryP M2TkV|IzOjd2M{m5
HF2303 Mn3tR5l1d3SxeHnjJGF{e2G7 MoXONVAxKM7:TR?= NEfRNoIzPCCq NWeyfZRLTE2VTx?= NYLSOmVXUUN3ME2wMlA3OCEQvF2= NEXndnIzOjJ5NEO5PS=>
HF2359 MYnDfZRwfG:6aXOgRZN{[Xl? MoXlNVAxKM7:TR?= MXeyOEBp NWjiR3JzTE2VTx?= M1;md2lEPTB;MD6wOlAh|ryP MVeyNlI4PDN7OR?=
HF2414 NH;xcFREgXSxdH;4bYMhSXO|YYm= NGjOVJQyODBizszN MVOyOEBp NWDtRoNOTE2VTx?= MlewTWM2OD1yLkC4NEDPxE1? NFrWTJYzOjJ5NEO5PS=>
A-673 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXxWGkyOCEQvF2= NHKyfZU6PiCq NHm4UpZFVVOR MWHJR|UxRTBwMEOyJO69VQ>? M1Xae|IyPDR6NUmx
TC-32 NWXoZo9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\1cFExKM7:TR?= NUW3N5BHQTZiaB?= NXTwbmVjTE2VTx?= M2DQW2lEPTB;MD6wN|kh|ryP NGXuSoQzOTR2OEW5NS=>
TC-71 M13rbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPtSZY3OTBizszN NX;0OoNYQTZiaB?= NV7PenBLTE2VTx?= M4nmfGlEPTB;MD6xNFIh|ryP MYKyNVQ1QDV7MR?=
SK-N-MC MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTNWm9WOTBizszN M{H0flk3KGh? NX3m[2J6TE2VTx?= MWfJR|UxRTBwMEeyJO69VQ>? M2G3N|IyPDR6NUmx
CHLA-9 M4myemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOxNEDPxE1? MnTGPVYhcA>? NV\lWm9HTE2VTx?= M2nZbWlEPTB;MD6wNVgh|ryP M2m3XVIyPDR6NUmx
CHLA-10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWexNEDPxE1? M1TCbVk3KGh? MYHEUXNQ NX;pfldNUUN3ME2wMlA3OCEQvF2= NU\NdYFYOjF2NEi1PVE>
CHLA-25 M3Pyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHywV|AyOCEQvF2= M2TmO|k3KGh? Ml7ZSG1UVw>? MU\JR|UxRTBwMU[4JO69VQ>? NUPObXg1OjF2NEi1PVE>
CHLA-32 NGL0RmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe2eVMyOTBizszN NVXpV|FYQTZiaB?= M2LQWmROW09? M3vmbWlEPTB;MD6xN|Yh|ryP NUnyfJZSOjF2NEi1PVE>
CHLA-56 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L5elExKM7:TR?= M1O1[|k3KGh? NX3URZUxTE2VTx?= NEXod|NKSzVyPUGwJO69VQ>? NIXaTokzOTR2OEW5NS=>
CHLA-258 NHnFcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPvcFEyOCEQvF2= NXjDTodVQTZiaB?= MWPEUXNQ M3z2PWlEPTB;MD6xN|Ih|ryP NGrMUIMzOTR2OEW5NS=>
COG-E-352 M4nSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTqNVAh|ryP M3LaR|k3KGh? MknFSG1UVw>? MYXJR|UxRTBwMESzJO69VQ>? MV:yNVQ1QDV7MR?=
CHLA-90 NIDqdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WzNlExKM7:TR?= M2e2Wlk3KGh? NGnXcmlFVVOR M3O4WmlEPTB;MD6wOlEh|ryP NYrVOpdGOjF2NEi1PVE>
CHLA-119 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGxNEDPxE1? M1;lNFk3KGh? M1jXWGROW09? NG\hRotKSzVyPUCuNFIzKM7:TR?= NWKxTmNpOjF2NEi1PVE>
CHLA-122 NG\3SlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxNEDPxE1? MX65OkBp M3juWWROW09? NFHvepVKSzVyPUCuNFE6KM7:TR?= NGOw[pAzOTR2OEW5NS=>
CHLA-136 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HpbVExKM7:TR?= M1\V[|k3KGh? M2K4TGROW09? M33ldmlEPTB;MD6wN|kh|ryP NI[5NXUzOTR2OEW5NS=>
CHLA-140 M37LZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke5NVAh|ryP MYC5OkBp NELIU3ZFVVOR NHG5RXZKSzVyPUCuNFI3KM7:TR?= NIO5NnAzOTR2OEW5NS=>
LA-N-6 NIPhZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vtcVExKM7:TR?= MlThPVYhcA>? NYe1[JNyTE2VTx?= MXvJR|UxRTBwMEW0JO69VQ>? NWnPc4FuOjF2NEi1PVE>
NB-1643 NV7hUohMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;EPWVIOTBizszN NWPvSJBbQTZiaB?= NGDXV2xFVVOR MXTJR|UxRTBwMEO3JO69VQ>? NV3JPWNZOjF2NEi1PVE>
NB-EBc1 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexNEDPxE1? MlTYPVYhcA>? MlXXSG1UVw>? MWjJR|UxRTBwMEWwJO69VQ>? MVWyNVQ1QDV7MR?=
SK-N-BE-1 NXzKUGs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:xNEDPxE1? NWDEe2pQQTZiaB?= M3y2NmROW09? NYHTPIx4UUN3ME2wMlAzQCEQvF2= MlK4NlE1PDh3OUG=
SK-N-BE-2 Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT5NVAh|ryP M2XHUlk3KGh? MmC5SG1UVw>? NGXQXWpKSzVyPUCuNFM3KM7:TR?= NFq2VowzOTR2OEW5NS=>
SMS-KAN NHj2N4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPxcHUyOCEQvF2= M13qdFk3KGh? MX7EUXNQ MVvJR|UxRTBwMEO0JO69VQ>? NUnEO5loOjF2NEi1PVE>
SMS-KANR NHe5R4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfRUWoyOCEQvF2= NVr2[Jo{QTZiaB?= MVvEUXNQ NGXzZVJKSzVyPUCuNFI3KM7:TR?= M4\z[|IyPDR6NUmx
SMS-KCN M3\ncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLDZmROOTBizszN MnvQPVYhcA>? M2D6RmROW09? MkXSTWM2OD1yLkCxPUDPxE1? M3rwPVIyPDR6NUmx
SMS-KCNR M2DaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLMNVAh|ryP M{nFXFk3KGh? NYnIXGtsTE2VTx?= MnXDTWM2OD1yLkCxNEDPxE1? M{f3eFIyPDR6NUmx
SMS-LHN M{Due2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDEelVyOTBizszN MoO2PVYhcA>? NIPBZYRFVVOR M1;ERWlEPTB;MD6wN|Ih|ryP MoXVNlE1PDh3OUG=
SMS-MSN MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13CW|ExKM7:TR?= M{XBd|k3KGh? NInvXo1FVVOR NWnte2VJUUN3ME2wMlAzOiEQvF2= M{\5ZVIyPDR6NUmx
SMS-SAN NHrFeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX2NVAh|ryP M4n2dFk3KGh? M2XpdWROW09? MmjETWM2OD1yLkCyNEDPxE1? NWfzTYNbOjF2NEi1PVE>
Granta-4 NX7DS4hMS3m2b4TvfIlkKEG|c3H5 MUexNEDPxE1? M4nxWVch\A>? M1j4VGlEPTB;MD6wOFAh|ryP NFX1U3YzOTJ7MUi2Oy=>
DB NYP0RlFwS3m2b4TvfIlkKEG|c3H5 M4fDTVExKM7:TR?= NWrMNJV5PyCm M2qwRmlEPTB;MD6wOFIh|ryP M4TWclIyOjlzOE[3
RL M3\EU2N6fG:2b4jpZ{BCe3OjeR?= MWmxNEDPxE1? NYfmbFVFPyCm M{DXbWlEPTB;MD6wNVUh|ryP NIr6SmIzOTJ7MUi2Oy=>
K562 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG2UI5NOTBizszN NWjHcJZVQTZiaB?= M{L3NGlEPTB;MD6wPFch|ryP M4rzcVIyODlzNkOz
LAMA-84 NGO2PZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPHdHIyOCEQvF2= NFzKVFk6PiCq MULJR|UxRTBwMEW3JO69VQ>? M1KwTFIyODlzNkOz
MM15 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XHbFQh|ryP M3z2TVczKGh? NYDGPFliTE2VTx?= MUTJR|UxRTBwMUOg{txO MWOyNFM5Ojh2NB?=
OPM1 M1nTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XLfFQh|ryP Mlz2O|IhcA>? MWLEUXNQ NGDRZ4dKSzVyPUCuNFMh|ryP M3nlbFIxOzh{OES0
RPM1 NFfjSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHXS2p[PCEQvF2= M4nNRlczKGh? MUPEUXNQ NXjFdWc{UUN3ME2xNE4{OiEQvF2= NUS1VolkOjB|OEK4OFQ>
INA6 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;mR|Qh|ryP NID6TIY4OiCq Ml33SG1UVw>? MVfJR|UxRTBwMECyJO69VQ>? MWKyNFM5Ojh2NB?=
OPM2 M{jaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonhOEDPxE1? NV[0fYtIPzJiaB?= MmP1SG1UVw>? MXrJR|UxRTRwM{eg{txO M1jaOVIxOzh{OES0
MM1R NV\zem5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP3OEDPxE1? NFvveFI4OiCq M1\QN2ROW09? MYrJR|UxRTFwNkig{txO MYOyNFM5Ojh2NB?=
DOX40 NYPpSZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37pZVQh|ryP NIHudm04OiCq M{XNUWROW09? NXT4PWJoUUN3ME21MlQ5KM7:TR?= M1XKd|IxOzh{OES0
LR5 NVW3ZpBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zwVFQh|ryP NVHpW4M1PzJiaB?= NY[xU4RsTE2VTx?= MnS5TWM2OD1{LkWzJO69VQ>? MUeyNFM5Ojh2NB?=
U266 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT6OEDPxE1? MV[3NkBp NWW3SZRITE2VTx?= M3yzOWlEPTB;MT60N{DPxE1? NWfxRnQ6OjB|OEK4OFQ>
RD NFzZbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonJNVAh|ryP NGfLWm86PiCq MnTQTWM2OD1yLkKyPEDPxE1? Moj2NlAyODh|M{i=
Rh41 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzSWWNZOTBizszN Mlq4PVYhcA>? NWTpNZlbUUN3ME2wMlA6OCEQvF2= M3TkPVIxOTB6M{O4
Rh30 M2XTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofnNVAh|ryP NH3rNXU6PiCq NXrCb2lCUUN3ME2wMlI{OCEQvF2= MYOyNFExQDN|OB?=
BT-12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS0NVAh|ryP M2HlNFk3KGh? NEWyVolKSzVyPUCuNFYxKM7:TR?= MXGyNFExQDN|OB?=
CHLA-266 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DBTlExKM7:TR?= NV;0WW8xQTZiaB?= MonGTWM2OD1yLkC3NkDPxE1? NEK0[JEzODFyOEOzPC=>
TC-71 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrtUZQyOCEQvF2= M2r2eFk3KGh? NELlPFlKSzVyPUCuNVAzKM7:TR?= M1u1b|IxOTB6M{O4
SJ-GBM2 NEjFeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P5UVExKM7:TR?= NH7B[WM6PiCq MXLJR|UxRTBwMEWwJO69VQ>? MVyyNFExQDN|OB?=
NALM-6 NUjsT2pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv4XYtGOTBizszN MVu5OkBp M{jNUmlEPTB;MD6wOlIh|ryP NIXIb4czODFyOEOzPC=>
COG-LL-317 NVLxVotvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;pVFExKM7:TR?= MmHOPVYhcA>? M3\FR2lEPTB;MD6wOFch|ryP M3LLbVIxOTB6M{O4
RS4-11 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnqNVAh|ryP MWK5OkBp NHzONmZKSzVyPUCuNFE5KM7:TR?= NULkbmNvOjBzMEizN|g>
MOLT-4 NWjVVY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrLUG4yOCEQvF2= NFm5T4Q6PiCq MY\JR|UxRTBwMEK2JO69VQ>? M33qc|IxOTB6M{O4
CCRF-CEM MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXGNVAh|ryP NGPMNJk6PiCq MVPJR|UxRTBwMEm0JO69VQ>? MkToNlAyODh|M{i=
Kasumi-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVexNEDPxE1? NF:0eGQ6PiCq MYfJR|UxRTBwMUCzJO69VQ>? NVrUNlNYOjBzMEizN|g>
Karpas-299 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjGNVAh|ryP NGDCT2U6PiCq MYDJR|UxRTBwMEO4JO69VQ>? NHvsfXYzODFyOEOzPC=>
Ramos-RA1 NF7nVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjFNYczOTBizszN NFG5W3A6PiCq NIPqVZdKSzVyPUCuNVI4KM7:TR?= MUiyNFExQDN|OB?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
細胞試験: [2]
+ 展開
  • 細胞株: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 24, 48, and 72 hours
  • 実験の流れ: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • 製剤: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • 投薬量: ~30 mg/kg/day
  • 投与方法: Orally
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
15% Captisol
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 518.92
化学式

C27H20ClFN4O4

CAS No. 1028486-01-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • 回答:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase信号経路図

Aurora Kinase Inhibitors with Unique Features

相関Aurora Kinase製品

Tags: Alisertib (MLN8237)を買う | Alisertib (MLN8237) ic50 | Alisertib (MLN8237)供給者 | Alisertib (MLN8237)を購入する | Alisertib (MLN8237)費用 | Alisertib (MLN8237)生産者 | オーダーAlisertib (MLN8237) | Alisertib (MLN8237)化学構造 | Alisertib (MLN8237)分子量 | Alisertib (MLN8237)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID